Exploring Cefiderocol Resistance Mechanisms in Burkholderia pseudomallei

被引：7
作者：
Hall, Carina M. M. [1 ]
Somprasong, Nawarat [1 ]
Hagen, Johannah P. P. [1 ]
Nottingham, Roxanne [1 ]
Sahl, Jason W. W. [1 ,2 ]
Webb, Jessica R. R. [3 ,4 ]
Mayo, Mark [3 ]
Currie, Bart J. J. [3 ]
Podin, Yuwana [5 ]
Wagner, David M. M. [1 ,2 ]
Keim, Paul [1 ,2 ]
Schweizer, Herbert P. P. [1 ,2 ]
机构：
[1] No Arizona Univ, Pathogen & Microbiome Inst, Flagstaff, AZ 86011 USA
[2] No Arizona Univ, Dept Biol Sci, Flagstaff, AZ 86011 USA
[3] Charles Darwin Univ, Menzies Sch Hlth Res, Global & Trop Hlth Div, Darwin, NT, Australia
[4] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Australia
[5] Univ Malaysia Sarawak, Inst Hlth & Community Med, Sarawak, Malaysia
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2023年 / 67卷 / 06期
关键词：
Burkholderia pseudomallei; cefiderocol; resistance; PSEUDOMONAS-AERUGINOSA; SUSCEPTIBILITY; CEFTAZIDIME; SEQUENCE;
D O I：
10.1128/aac.00171-23
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Cefiderocol is a siderophore cephalosporin designed mainly for treatment of infections caused by beta-lactam and multidrug-resistant Gram-negative bacteria. Burkholderia pseudomallei clinical isolates are usually highly cefiderocol susceptible, with in vitro resistance found in a few isolates. Resistance in clinical B. pseudomallei isolates from Australia is caused by a hitherto uncharacterized mechanism. Cefiderocol is a siderophore cephalosporin designed mainly for treatment of infections caused by beta-lactam and multidrug-resistant Gram-negative bacteria. Burkholderia pseudomallei clinical isolates are usually highly cefiderocol susceptible, with in vitro resistance found in a few isolates. Resistance in clinical B. pseudomallei isolates from Australia is caused by a hitherto uncharacterized mechanism. We show that, like in other Gram-negatives, the PiuA outer membrane receptor plays a major role in cefiderocol nonsusceptibility in isolates from Malaysia.
引用
收藏
页数：5
相关论文
共 33 条
  • [1] Burkholderia pseudomallei Clinical Isolates Are Highly Susceptible In Vitro to Cefiderocol, a Siderophore Cephalosporin
    Burnard, Delaney
    Robertson, Gemma
    Henderson, Andrew
    Falconer, Caitlin
    Bauer, Michelle J.
    Cottrell, Kyra
    Gassiep, Ian
    Norton, Robert
    Paterson, David L.
    Harris, Patrick N. A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (02)
  • [2] Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei
    Chantratita, Narisara
    Rholl, Drew A.
    Sim, Bernice
    Wuthiekanun, Vanaporn
    Limmathurotsakul, Direk
    Amornchai, Premjit
    Thanwisai, Aunchalee
    Chua, Hui Hoon
    Ooi, Wen Fong
    Holden, Matthew T. G.
    Day, Nicholas P.
    Tan, Patrick
    Schweizer, Herbert P.
    Peacock, Sharon J.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (41) : 17165 - 17170
  • [3] Transcriptional and post-transcriptional regulation of PenA β-lactamase in acquired Burkholderia pseudomallei β-lactam resistance
    Chirakul, Sunisa
    Norris, Michael H.
    Pagdepanichkit, Sirawit
    Somprasong, Nawarat
    Randall, Linnell B.
    Shirley, James F.
    Borlee, Bradley R.
    Lomovskaya, Olga
    Tuanyok, Apichai
    Schweizer, Herbert P.
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [4] Clinical and Laboratory Standards Institute, 2021, Performance standards for antimicrobial susceptibility testing
  • [5] Treatment and prophylaxis of melioidosis
    Dance, David
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2014, 43 (04) : 310 - 318
  • [6] Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design
    Huband, Michael D.
    Ito, Akinobu
    Tsuji, Masakatsu
    Sader, Helio S.
    Fedler, Kelley A.
    Flamm, Robert K.
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2017, 88 (02) : 198 - 200
  • [7] In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria
    Ito, Akinobu
    Sato, Takafumi
    Ota, Merime
    Takemura, Miki
    Nishikawa, Toru
    Toba, Shinsuke
    Kohira, Naoki
    Miyagawa, Satoshi
    Ishibashi, Naoki
    Matsumoto, Shuhei
    Nakamura, Rio
    Tsuji, Masakatsu
    Yamano, Yoshinori
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (01)
  • [8] Cefiderocol: a promising antibiotic against multidrug-resistant Gram-negative bacteria
    Jean, Shio-Shin
    Hsueh, Shun-Chung
    Lee, Wen-Sen
    Hsueh, Po-Ren
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2019, 17 (05) : 307 - 309
  • [9] Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
    Karakonstantis, Stamatis
    Rousaki, Maria
    Kritsotakis, Evangelos, I
    [J]. ANTIBIOTICS-BASEL, 2022, 11 (06):
  • [10] Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)
    Kohira, Naoki
    Hackel, Meredith A.
    Ishioka, Yoshino
    Kuroiwa, Miho
    Sahm, Daniel F.
    Sato, Takafumi
    Maki, Hideki
    Yamano, Yoshinori
    [J]. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2020, 22 : 738 - 741
1234